Emergent Biosolutions Inc (EBS) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.28. Analysts had a consensus of $-0.12. The company posted revenue of $111.00 million in the period, compared to analysts expectations of $107.57 million. The company’s revenue was up 74.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.50 EPS.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Chardan Capital Markets Initiated Emergent Biosolutions Inc on Apr 15, 2016 to “Buy”, Price Target of the shares are set at $47.Singular Research Initiated Emergent Biosolutions Inc on Mar 28, 2016 to “Buy”, Price Target of the shares are set at $44.Emergent Biosolutions Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Emergent Biosolutions Inc closed down -1.3 points or -3.31% at $37.95 with 3,30,333 shares getting traded on Wednesday. Post opening the session at $38.94, the shares hit an intraday low of $37.92 and an intraday high of $38.94 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 25, 2016, Fuad El-hibri (Chairman) sold 4,209 shares at $40.50 per share price. According to the SEC, on Apr 20, 2016, Daniel Abdun-nabi (President & CEO) sold 8,702 shares at $40.17 per share price. On Apr 8, 2016, Robert Kramer (EVP, Corporate Services Divisi) sold 21,786 shares at $38.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.